Director Fred A Middleton purchases 248,972 shares of CALC at $0.80; stock 88.6% below 52-week high
Director Fred A Middleton purchased 248,972 shares of CalciMedica at $0.80 on 2026-06-25, increasing his holdings by +30.6% to 1.06M shares total. At the current price of $0.82, the stock trades 88.6% below its 52-week high of $7.20, though it has risen +44.1% over the prior 90 days and +10.1% over the prior 30 days. His prior trades at CALC show mixed outcomes: 1 of 5 prior buys achieved positive 90-day returns, suggesting limited track record of well-timed entry timing at this ticker. The company reported net income of $4,976,000.00, though it was unprofitable over its most recent full fiscal year, creating context of elevated execution risk despite near-term price momentum.
Director MIDDLETON FRED A buys 4,800 shares at $2.65; stock down 61.6% from 52-week high, company unprofitable.
Director Middleton purchased 4,800 shares at $2.65 on 2024-12-06, increasing his holdings by 15.1% to 36.5K shares. The purchase occurs in a deteriorating price environment: the stock is -61.6% from its 52-week high and down 18.3% over the prior 30 days. CalciMedica is unprofitable (net income -$5.6M) with a modest market cap of $38.6M. Notably, Middleton's prior two buys at this same ticker (on 2024-11-01) are currently underwater at -8.0% over 30 days, while his cross-ticker track record shows an 80.00% 90-day win rate with +15.6% average return. This transaction shows a director adding shares despite deteriorating fundamentals and recent price weakness, and notably following his recent November purchases which have not yet produced gains.
Director Middleton bought 107,744 shares at $3.75; stock down 52.4% from 52-week high; unprofitable firm with cluster buy activity
Director Fred A Middleton executed 3 separate purchases totaling 107,744 shares for $404,040.00 at $3.75 on 2024-11-01, while CalciMedica's stock trades at $3.54, down 52.4% from its 52-week high and down 23.0% over 90 days. The company reported net income of $-4.0M, indicating unprofitability in its most recent full fiscal year. Notably, Middleton's cross-ticker track record shows 80.00% 90-day win rate with prior buys averaging +15.6% returns, while his 5 prior purchases at CALC on 2024-01-23 were all well-timed at the 90-day mark. The current filing coincides with a cluster of 4 other insider purchases within the past 14 days, representing coordinated acquisition activity at a depressed valuation point after sustained price deterioration.
